DAFTAR PUSTAKA

Abbaspour Babaei, M. 2016. DDDT-89114-receptor-tyrosine-kinase-ckit-inhibitors-a-therapeutic-t, Drug Design, Development and Therapy, 10, pp. 2443–2459.

Adriani. 2018. Prediksi senyawa bioaktif dari tanaman sarego (Lunasia amara Blanco) sebagai inhibitor enzim siklooksigenase-2 (cox-2) melalui pendekatan molecular docking. *Jurnal Ilmiah Pena,* 1(1), 6–11.

Ahmed, J., Salim, K.A., Lim, L.B.L., and Jama, A.M., 2019. Evaluation of antioxidant activity and phytochemical screening of leaves, barks, stems and fruits of *alphitonia philippinensis (rhamnaceae)* from brunei darussalam. *Pharmacognosy Journal*, 11 (5), 951–961.

Akbar, N.A., Winda, T.W. 2022. Studi In Silico Senyawa yang Terkandung dalam Tanaman Daun Sirih Merah (Piper crocatum RUIZ & PAV) sebagai Kandidat Anti SARS CoV-2. Prosiding seminar nasional diseminasi. 2(1). 378-391.

Al Omar, R., Micklewright, R., Masud, K., Naz, T., Vemulpad, S., and Jamie, J., 2022. The genus *alphitonia reissek ex endl. (rhamnaceae)*: a review of its customary uses, phytochemistry and biological activities. *Journal of Ethnopharmacology*, 294, 115168. 1-24.

Alteri, R., Andrews, K., Barzi, A. 2017. *Colorectal Cancer Facts & Figure. 2017-2019*. Atlanta: American Cancer Society.

Andyana, I.W.L. 2017. *Limfoma Hodgkin*. Bali: Bagian Ilmu Penyakit Dalam Rsup Sanglah Universitas Udayana.

Arwansyah., Ambarsari, L., dan Sumaryada, T. 2014. Simulasi *Docking* Senyawa Kurkumin dan Analognya Sebagai Inhibitor Reseptor Androgen pada Kanker Prostat. *Journal Current Biochemistry*, 1 (1).

Ballante F, Marshall GR. 2016. Strategi Otomatis untuk Pemilihan Pose Pengikatan dan Penilaian Docking dalam Desain Obat Berbasis Struktur. *Jurnal Informasi dan Pemodelan Kimia* . 56 (1): 54–72.

Bare, Y., Helvina, M., Elizabeth, A., & Sari, D. R. T. 2019. *Potensi Asam Kafeat Pada Kopi Sebagai Simultan Gen Peroxixme Proliferator-Activated Receptor Gamma (Ppar-γ)*: Studi in Silico. Saintek Lahan Kering 2(2): 52–53.

Bernaldez, M. J. A., Billones, J. B., & Magpantay, A. 2018. In silico analysis of binding interactions between GSK983 and human DHODH through docking and molecular dynamics. AIP Conference Proceedings. vol. 2045(1): 020073-1 020073-8.

Caldeira, S., Timmins, F., de Carvalho, E. C., & Vieira, M. 2017. *Spiritual Well-Being and Spiritual Distress in Cancer Patients Undergoing Chemotherapy: Utilizing the SWBQ as Component of Holistic Nursing Diagnosis*. Journal of Religion and Health, 56(4), 1489–1502.

Cartika, H. 2016. *Modul Bahan Ajar Cetak Farmasi Kimia Farmasi*. Jakarta. Kementrian Kesehatan Republik Indonesia, p: 21.

Chairunnisa, A., & Runadi, D. 2017. Aktivitas Kalkon terhadap Reseptor Esterogen β (Er-β) Sebagai Antikanker Payudara Secara In Vitro Dan In Silico: Review. *Farmaka,* 14, 1–8.

Dallakyan, S., & Olson, A. J. 2015. Small-molecule library screening by docking with PyRx. *In Chemical biology*. New York, NY. Humana Press, pp. 243-250.

De Roock W, Jonker DJ, Di Nicolantonio F. 2013. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy refractory metastatic colorectal cancer treated with cetuximab. *JAMA.* 304, 1812-1820.

Desen, W., & Japaries, W. 2013. *Onkologi Klinis*. Jakarta: Fakultas Kedokteran Universitas Indonesia.

Dhanyamraju, P.K. & Patel, T.N., 2022. Melanoma therapeutics: a literature review. *Journal of Biomedical Research*, 36 (2), 77–97.

Dienstmann, R., Salazar, R., Tabernero, J. 2015. Personalizing Colon Cancer Adjuvant Therapy: Selecting Optimal Treatments for Individual Patients. *J Clin Oncol* 2014.60.0213.

Dona, R., Neni, F., Ikhsan, I., Benni.I., Fikri, M., & Nova, T. S. 2019. Studi In Silico, Sintesis, dan Uji Sitotoksik Senyawa P-Metoksi Kalkon Terhadap Sel Kanker Payudara MCF-7. *Jurnal Sains Farmasi & Klinis.* 6(3): 243–249.

Douillard JY, Oliner KS, Siena S, Tabernero J, Burkes R, Barugel M. 2013. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. *N Engl J Med*. 369(11). 1023-1034.

Ellis, H., & Mahadevan, V., 2017. *Clinical anatomy, applied anatomy for students and junior doctors.* Oxford: Wiley-Blackwell. 11, 119-121.

Fatchiyah, E. L., Arumingtyas S., Widyarti, & Rahayu, S. 2011. *Biologi Molekuler: Prinsip Dasar Analisis*. Jakarta: Erlangga.

GLOBOCAN. 2020. World Health Organization Internasional Agency for Research on Cancer (IARC). *Indonesia Source*: Globocan 2020.

Goodwin, R.J.A. Bunch, and D.F. McGinnity.2017. Mass Spectrometry Imaging in Oncology Dryg Discovery *In*: Advances in Cancer Research, USA: Academic Press.

Hadi, A.N. 2023. *Molecular Docking* Aktivitas Anti-Melanoma Senyawa Dari Genus *Alphitonia* Menggunakan *PLANTS®*. *Skripsi*. Sarjana Farmasi. Banjarbaru: Universitas Borneo Lestari.

Hakozaki, S. Y., Sameshima, T., Tatsuoka. 2017. Rectal carcinoma and multiple gastrointestinal stromal tumors (GIST) of the small intestine in a patient with neurofibromatosis type 1: a case report. *World Journal of Surgical Oncology*. 6 (32): 112-117.

Hardjono, S. 2013. Sintesis dan uji aktivitas antikanker senyawa 1-(2-klorobenzoiloksi)urea dan 1-(4-klorobenzoiloksi)urea. *Berkala Ilmiah Kimia Farmasi*, 2 (1), 16-21.

Jasmine, S. H. 2021. Analisis In Silico Kandungan Senyawa Kimia Tumbuhan Sambiloto *(Andrographis paniculata)* Terhadap Reseptor Histamin H2 Sebagai Anti Tukak Lambung. *Skripsi*. Sarjana Farmasi. Universitas Sumatera Utara.

Johnson, C. M., Wei, C., Ensor, J. E. 2014. Meta-analyses of colorectal cancer risk factors. *National Institute of Health*, 24: 1207–1222.

Kim, S. 2016. *Getting The Most Out Of Pubchem For Virtual Screening, Expert Opinion on Drug Discovery*. U.S.A. Taylor and Francis Ltd, pp. 843–855.

Komite Penanggulangan Kanker Nasional. 2014. *Pedoman Nasional Pelayanan Kedokteran Kanker Kolorektal*. Jakarta : Komite Penanggulangan Kanker Nasional.

Labianca, R., Beretta, G. D., Kildani, B., Milesi, L., Merlin, F., Mosconi, S., Wils, J. 2014. Colon cancer. *Critical Reviews in Oncology/Hematology*. 4(2), 106–133.

Lee, H. N., Jang, H. Y., Kim, H. J., Shin, S.A., Choo, G.S., Park, Y. S. 2016. Antitumor and apoptosis-inducing effects of α-mangostin extracted from the pericarp of the mangosteen fruit (*Garcinia mangostana L.*) in YD-15 tongue mucoepidermoid carcinoma cells. *Int J Mol Med*; 37 (4): 939-48.

Li, Q.; Ren, F.Q.; Yang, C.L.; Zhou, L.M.; Liu, Y.Y.; Xiao, J.; Zhu, L.; Wang, Z.G. 2015. Anti-proliferation effects of isorhamnetin on lung cancer cells in vitro and in vivo. Asian Pac. *J. Cancer Prev.* 16, 3035–3042

Lipinski, C. A. 2016. Rule of five in 2015 and beyond: Target and ligand structural limitations, ligand chemistry structure and drug discovery project decisions. *Advanced Drug Delivery Reviews*, pp. 34–41.

Lipinski, C.A., Lombardo, F., Dominy, B.W., & Feeney, P.J., 1997. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. *Adv. Drug Deliv. Rev.* 23, 3-25.

Liu, K., Tang., M., Han, X., Jin, H., Zhu, H. 2020. Hydroxychloroquine, a less toxic derivate of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. *Cell Discovery*, 6(1), 1-4.

Mardianingrum, R., Bachtiar, K. R., Susanti, S., Aas Nuraisah, A. N., & Ruswanto, R. 2021. Studi In Silico Senyawa 1,4-Naphthalenedione-2- Ethyl-3-Hydroxy sebagai Antiinflamasi dan Antikanker Payudara. *ALCHEMY Jurnal Penelitian Kimia*, 17(1), 83

Martati, T., Mumpuni, E., Mulatsari, E., & Maryanto, K. 2019. Analisis Selektivitas Senyawa Turunan Diosmetin Sebagai Antioksidan Baru dengan menggunakan Metode Molecular Docking. *Jurnal Farmasi Indonesia,* 10 (4), 25-31.

Mondal A., Gandhi A., Fimognari C., Antas G., Bishayye A. 2019. Alkaloids for cancer prevention and therapy: Current progress and future perspectives. *European Journal of Pharmacology*. 19 (3042), 1-25.

Nakamura, K.; Shimura, N.; Otabe, Y.; Hirai-Morita, A.; Nakamura, Y.; Ono, N.; Ul-Amin, M.A.; Kanaya, S. 2013. KNApSAcK-3D: A Three-Dimensional Structure Database of Plant Metabolites. *Plant Cell Physiol*. 54, e4.

Nor, Muhamad Fajrin. 2023. Studi *In Silico* Senyawa Genus *Alphitonia* Sebagai Kandidat Anti Kanker Serviks Menggunakan *Molecular Docking PLANTs*. *Skripsi*. Sarjana Farmasi. Banjarbaru: Universitas Borneo Lestari.

Paramita, A., Dasna, I. W., Yahmin, Y. 2019. Integrasi STEM untuk Keterampilan Argumentasi dalam Pembelajaran Sains. *Jurnal Pembelajaran Kimia*, 4(2), 92–99.

Pissarra A, Malheiro M, Matos LV, Plácido AN. 2019. Severe rhabdomyolysis related to oxaliplatin adjuvant therapy for colorectal cancer. *BMJ Case.*

Pratama, M.R.F. 2015. Molecular Docking of Anticanced Agents: Artemsinin and

Derivatives as HER2 Inhibitor. *Proceedings of 1st Sari Mulia International Conference on Health and Science 2015*. Banjarmasin.

Purnomo, H., 2013. *Kimia Komputasi Untuk Farmasi dan Ilmu Terkait Uji in Siliko Senyawa Antikanker.* Yogyakarta, Pustaka Pelajar.

Rizqhan., 2014. Hubungan indeks eritrosit dan kadar hemoglobin terhadap lokasi tumor pada pasien kanker kolorektal. *Jurnal Media Medika Muda.*

Rose, P.W., Andreas, P., Chunxiao, B., Wolfgang, B., Cole, C., Shucismita, D., Kramer, G., David, G., John, W., Jesse, W., Jasmine, Y., Christine, Z., Helen, B., Philip, B., and Stephen, B. 2015. The RCSB Protein Data Bank: Views of structural biology for basic and applied research and education. *Nucleic Acids Research*, 43(D1), pp. D345–D356.

Ruswanto. 2015. Molekular docking empat turunan isonicotinohydrazide pada Mycobacterium tuberculosis enoyl-acyl carrier reductase (InhA). *Jurnal Kesehatan Bakti Tunas Husada*. 13: 213–227.

Santosa, H., & Kesuma, D. 2018. Aktivitas Antikanker Senyawa N-Etil-N-Feniltiourea secara In Silico dan In Vitro. *Kongres XX dan Pertemuan Ilmiah Tahunan Ikatan Apoteker Indonesia*, p.636.

Sathiya, R., Angam, T. Salammal, R., Sasirekha, S., Sivasubramanian, & Dinesh, M. 2019. Artikel asli biomedis & farmakoterapi adalah fitoterapi berbasis kompleks rutin-fucoidan baru untuk kanker serviks melalui pencapaian peningkatan bioavailabilitas dan apoptosis sel kanker. *Biomedis & Farmakoterapi*, jilid. 109, hlm.1181–1195.

Shacham Shmueli, E., Geva, R., Yarom, N., Hubert, A., Keynan, R., Kedem, T.H., Eini, M., Tamarkin, D., Shirvan, M. 2019. Topical doxycycline foam 4% for prophylactic management of epidermal growth factor receptor inhibitor skin toxicity: an exploratory phase 2, randomized, double-blind clinical study. *Support Care Cancer*. 27: 3027–3033.

Shanker M, Jin J, Branch CD, Miyamoto S, Grimm EA, Roth JA, Ramesh R. 2016. Tumor suppressor gene-based nanotherapy : from test tube to the clinic. *J Drug Deliv*; 1-10.

Sigh, D., Tripathi, D. 2020. *Frontiers in Protein Structure, Function, and Dynamics*, Singapore. Hill University: India.

Sinurat, M. R., Rahmayanti, Y., & Rizarullah, R. 2021. Uji Aktivitas Antidiabetes Senyawa Baru Daun Yakon (Smallanthus sonchifolius) sebagai Inhibitor Enzim DPP-4: Studi in silico. *Jurnal IPA & Pembelajaran IPA*, 5(2), 138-150 https://doi.org/10.24815/jipi.v5i2.20068.

Singh, S., Gupta, A. K., & Verma, A. 2013. Molecular Properties and Bioactivity score of the Aloe vera antioxidant compounds in order to lead finding. *Journal of Pharmaceutical, Biological and Chemical Sciences*, 4(2), 876–881.

Siswandono. 2016. *Pengembangan Obat In* : Siswandono. Kimia Medisinal 1, edisi kedua. Surabaya: Airlangga University Press, pp. 11-27.

Suhud, F. 2015. Uji Aktivitas In-silico Senyawa Baru 1-Benzil-3-benzoilurea Induk dan Tersubstitusi sebagai Agen Antiproliferatif. *Jurnal Farmasi Indonesia*, 7(4), 245–251.

Syahputra, G., Ambarsari L, & T, S. 2014. Simulasi docking kurkumin enol, bisdemetoksikurkumin dan analognya sebagai inhibitor enzim12-lipoksigenase. *Biofisika*, *10*(1), 55–67.

Syamsudin. 2014. Farmakologi Molekuler Mekanisme Kerja Obat pada Tingkat Molekul. Jakarta: Penerbit Buku Kedokteran.

Tabernero J, Yoshino T, Cohn AL, dkk. 2015. Ramucirumab versus plasebo dalam kombinasi dengan FOLFIRI lini kedua pada pasien dengan karsinoma kolorektal metastatik yang berkembang selama atau setelah terapi lini pertama dengan bevacizumab, oxaliplatin, dan fluoropyrimidine (RAISE): studi fase 3 acak, tersamar ganda, multisenter. *Lancet Oncol*; 16 :499–508.

Tresnaasih, I. 2020. *Sistem Pencernaan Pada Manusia*. Jakarta. Kementerian Pendidikan dan Kebudayaan.

Yanuar A. 2013. *Penambatan molekuler*. Praktek dan Aplikasi pada Virtual Screening. Depok: Fakultas Farmasi Universitas Indonesia; 43-93.

Yarom, N. & Jonker, D.J., 2019. The role of the epidermal growth factor receptor in the mechanism and treatment of colorectal cancer. *Discovery medicine*, 11(57): 95-105.

Zhang, L., Lv, Z., Xu, J., Chen, C. Q., Li, P., Wei, D., Wu, Z., Sun, X. 2018. MicroRNA-134 menghambat angiogenesis dan proliferasi osteosarkoma dengan menargetkan jalur VEGFA/VEGFR1. *FEBS J.* 285, 1359–1371.

LAMPIRAN

Lampiran 1. Aplikasi dan Web Penunjang yang Digunakan

Icon Aplikasi		
Dalam Aplikasi	*Marvin Sketch*	
	Discovery Studio	
	Yasara	

	PLANTS	
Web Penunjang	Pubchem	
	PDB	
	Uji *Lipinski*	

Lampiran 2. Tahapan Preparasi Protein dan *Native Ligand*

Load File Protein	
Penghapusan Air	
Penambahan Hidrogen	

Penghapusan Rantai yang tidak digunakan (Preparasi Protein); Penghapusan protein (sisakan *native ligand*)	
Penyimpanan Hasil Preparasi	

Lampiran 3. Tahapan Preparasi Ligand Senyawa Pembanding dan Senyawa Uji

Buka *Marvin Sketch*, Load File Protein/Gambar Struktur Ligan	
Clean 2D ligand	
Protonasi di PH 7,4	
Simpan Hasil Preparasi dengan Nama ligand2D.mrv	

Pembuatan Konformasi	
Penyimpanan Hasil Konformasi dengan nama ligan.mol2	

Lampiran 4. Tahapan Validasi Protein dan Penetapan RMSD

Validasi Protein	Siapkan Folder Untuk Validasi Protein dengan PLANTS	
	Masukkan ke Folder File Protein dan *Ligand Native* yang sudah dipreparasi	
	Docking Senyawa *Native Ligand* dengan PLANTS	
Penetapan RMSD	Load File ref_ligand.mol2	

	Load *ligand native* hasil docking	
	Hapus Hydrogen	
	Klik analys kemudian RMSD of molecules	

	Sesuaikan Parameter	
	Lihat Hasil	

Lampiran 5. Tahapan Docking Senyawa

Siapkan Folder dan File	
Masukkan perintah “plants—mode bind ref_ligand.mol2 5 protein.mol2”	
Ubah Kordinat protein di File Config dengan di layer plants	
Masukkan perintah “plants==mode screen config.txt”	

Tunggu Proses *Docking*	
Lihat Hasil di Folder “result/best ranking”	

Lampiran 6. Tahapan Visualisasi Ikatan Senyawa dan Protein

Load File Protein	
Insert *Ligand*	 

	
Atur Parameter	 
Show 2D	

Lampiran 7. Tahapan Uji Lipinski

Siapkan Ligand Dalam Bentuk .pdb	
Buka Website Uji *Lipinski*	
Pilih File *Ligand*	
Submit	

Cek Result	

Lampiran 8. Hasil RMSD Protein Kanker Kolorektal

Protein (Reseptor)	Konformasi	Skor Docking	RMSD
4HJO	1	-103.046	1.4746
(Epidermal Growth	2	-103.022	1.4720
Factor Reseptor)	3	-102.489	1.5304
	4	-102.611	1.4335
	5	-102.363	1.4688
	6	-102.969	1.4942
	7	-102.671	1.4658
	8	-100.297	1.9648
	9	-101.972	1.4679
	10	-102.529	1.5809
2P2I	1	-113.492	1.0514
(Vascular Endothelial	2	-111.546	0.8169
Growth Factor	3	-115.511	1.5294
Receptor)	4	-119.197	1.4272
	5	-116.343	1.0921
	6	-115.201	1.0961
	7	-117.339	1.1748
	8	-112.438	1.3510
	9	-118.818	1.0809
	10	-117.435	1.2152

Keterangan : Nilai yang terpilih dan memenuhi parameter RMSD <2

Lampiran 9. Hasil Docking, Visualisasi, dan Residu Asam Amino Senyawa Genus *Alphitonia*

No	Senyawa/ Ligand	Conformer	Protein		Visualisasi		Residu Asam Amino	
			4HJO	2P2I	4HJO	2P2I	4HJO	2P2I
1	*Native*	1	-103.046	-113.492			LYS A:721 | VAL A:702 | ALA A:719 | LEU A:820 | LEU A:694	CYS B:1024 | LEU B:1019 | LEU B:1035 | ALA B:866 | VAL B:916 | VAL B:848 | LEU B:889
		2	-103.022	-111.546			LEU A: 764 | GLN A: 767	PHE B:918 | GLU B:917
		3	-102.489	-115.511			CYS A:773 | MET A:769 | LYS A:704	CYS B: 919 | GLU B: 885
		4	-102.611	-119.197			LEU A: 768 | GLY A: 772	VAL B: 899
		5	-102.363	-116.343				
		6	-102.969	-115.201				
		7	-102.671	-117.339				
		8	-100.297	-112.438				
		9	-101.972	-118.818				
		10	-102.529	-117.435				
2	Cetuximab	1	-100.435	-		-	LEU A:768 | MET A:769 | LEU A:820 | CYS A:773 | LEU A:694 |	-

							MET A:742 | LEU A: 753 | LEU A:764 | LEU A:834 | LYS A:721 | VAL A:702 LEU A: 694	
		2	-102.208	-			ASP A:831	-
		3	-96.5392	-			PHE A:832	-
		4	-96.5	-			THP A:830	-
		5	-101.637	-				-
		6	-99.8231	-				-
		7	-102.28	-				-
		8	-103.618	-				-
		9	-100.211	-				-
		10	-98.2228	-				-
3	Bevacizumab	1	-	-82.5468	-		-	ALA B:866 | CYS B:1045 | VAL B:916 | VAL B:899 | LEU B:1035 | PHE B:1047 | VAL B:848
		2	-	-82.8146			-	CYS B: 919 | ASP B:1046
		3	-	-83.0241			-	LYS B:868
		4	-	-83.0043			-	PHE B:918
		5	-	-82.7775			-	
		6	-	-83.0624			-	

		7	-	-82.4448			-	
		8	-	-81.5948			-	
		9	-	-83.1842			-	
		10	-	-82.2371			-	
4	*Alphitonin*	1	-86.0803	-82.4066			THR A:766	GLU B: 917 | VAL B: 914 | GLU B: 885 | CYS B: 1045
		2	-86.202	-82.2836			THR A: 830 | GLN A: 767 | THR A: 766 | LEU A: 764 | ALA A: 719	ALA B: 866 | CYS B:919 | LEU B: 1035 | VAL B: 848 | VAL B: 916
		3	-86.0102	-82.6572			LEU A:820	LYS B: 868
		4	-85.8695	-82.0613			LYS A:721	LYS B: 868
		5	-85.659	-81.2354				

		6	-86.0733	-82.0079				
		7	-86.0323	-81.6469				
		8	-85.8145	-81.4153				
		9	-85.9173	-82.4718				
		10	-85.9905	-82.6294				
5	*2-Ketobetulinic acid*	1	-67.634	-73.7887			THR A: 766	ARG B: 1027
		2	-68.9177	-72.2763			ALA A:719 | ARG A: 817 | CYS A: 773 | LEU A: 775 | LEU A:694 | MET A: 769 | VAL A: 702	ALA B: 881 | CYS B: 1024 | ILE B: 888 | ILE B: 892 | LEU B: 1019
		3	-65.3384	-73.8581			LYS A: 721	
		4	-67.1968	-73.1844			THR A: 830 | LEU A:820	
		5	-65.6779	-74.0362				
		6	-64.237	-72.3278				
		7	-63.6233	-72.1531				
		8	-64.5664	-71.5721				
		9	-65.6164	-73.0385				
		10	-64.1166	-71.6005				
6	*Alphitolic acid*	1	-66.9985	-74.2965			LYS A: 721	ARG B: 1027
		2	-66.9249	-74.1826			THR A: 830 | LEU A: 820	ALA A: 881 | CYS B: 1024 | ILE B: 892 | ILE

								B: 888 | LEU B: 1019 | HIS B: 1026
		3	-68.411	-73.4419			ALA A:719 | ARG A: 817 | CYS A: 773 | LEU A: 775 | LEU A: 694 | MET A: 769 | VAL A: 702	ARG B: 1027
		4	-67.3483	-74.4963				
		5	-66.9935	-74.0681				
		6	-67.8034	-74.384				
		7	-67.9811	-72.7907				
		8	-67.0314	-74.1228				
		9	-68.7571	-71.7842				
		10	-67.5214	-74.2374			LYS A: 721	
7	*3-O-Cis-p-Coumaroyl aphitolic acid*	1	-87.6377	-85.0584			CYS A: 751 | CYS A:773 | ASP A: 831	GLU B:885
		2	-86.79	-88.3605				ARG B:1027
		3	-88.2855	-85.9986				HIS B:1026
		4	-86.0648	-88.7478				CYS B:1045
		5	-93.266	-87.2428			LEU A: 820 | LEU A: 694 | LYS A:721	VAL B:899 | TYR B:1082 | ILE B:888
		6	-84.8468	-88.4604				LEU B:889
		7	-84.7635	-88.6802				
		8	-90.8286	-88.5672			ARG A: 752	
		9	-82.7416	-83.6603			THR A: 830	
		10	-82.8859	-82.4549			LEU A: 753 | LEU	

							A:768 | LYS A:704 | VAL A: 702	
8	*3-O-p-Trans-7-Coumaroyl aphitolic acid*	1	-84.1539	-82.4614			THR A: 830	CYS B:919 GLU B:885 ASP B:1046
		2	-84.3599	-82.9554			ASP A: 831 | MET A: 769 | THR A: 766 | LYS A: 721	LYS B:868
		3	-88.6126	-79.2032			ALA A: 719 | LEU A: 694 | LEU A: 820	LEU B:1035 ALA B:866 LEU B:840
		4	-88.5996	-78.309			LYS A: 721	PHE B:1047 VAL B:867
		5	-88.7004	-78.5425				VAL B:848 VAL B:916
		6	-88.401	-75.172				
		7	-84.2853	-84.0819				
		8	-83.5137	-84.3679				
		9	-88.4057	-77.5611				
		10	-84.2864	-80.0858				
9	*Rutin*	1	-104.489	-78.788			ALA A:719 | LEU A:820	LYS B: 868
		2	-99.421	-76.6357			VAL A:702	ILE B: 1019 | ILE B: 892 | ILE
		3	-97.9603	-75.1807			MET A:769 LEU A:694	

							ASP A:831 ASN A:818 LYS A:721	B: 888 | LEU B: 889 | LEU B:882
		4	-98.8269	-73.4409			ARG A:817 SER A:696	ILE B: 1025 | ASP B: 1046 | GLN B:847 | ME T B: 869
		5	-97.6836	-73.3849				ALA B: 881
		6	-100.31	-76.7891				
		7	-104.646	-81.0856				
		8	-98.8224	-76.4757				
		9	-99.7808	-75.1797				
		10	-98.5519	-80.8015				
10	*Stigmasterol*	1	-95.7533	-83.6522			ALA A:719 | CYS A: 773 | LEU A: 694 | LEU A: 834 | LYS A: 721 | VAL A: 702	ILE B:1025
		2	-94.6749	-79.6349				ILE B: 1025
		3	-96.0936	-83.5991				VAL B:899 VAL B:916 ILE B:888 LEU B:889 CYS B:1045 PHE B:1047 LEU B:1035 CYS B:1024 HIS B: 1026 | LEU B:1019
		4	-96.0782	-83.6963			LEU A: 820	
		5	-95.5731	-85.3837				
		6	-95.7595	-82.4836				

		7	-95.5554	-82.6402				
		8	-94.9074	-83.8036				
		9	-94.6798	-84.7883				
		10	-94.97	-80.9184				
11	*2α-Formyl-A(1)norlup-20 (29)-en-28- oic acid*	1	-63.8425	-65.297			CYS A: 773 | LYS A: 721	ALA B: 881 | CYS B:1024 | HIS B: 1026 | LEU B: 889 | LEU B:1019 | ILE B:888
		2	-64.8717	-65.1465			ARG A: 817 | LEU A: 694 | LEU A: 820 | MET A: 769 | VAL A: 702	
		3	-64.0649	-65.2696				
		4	-64.0966	-65.7025				
		5	-65.5495	-65.3963				
		6	-64.6864	-66.0064				
		7	-64.4113	-66.3795				
		8	-67.5873	-65.3946				
		9	-66.574	-65.1002				
		10	-64.7808	-63.0723				
12	*Kaempferol-3-rutinoside*	1	-96.6792	-81.0359			ALA A: 719 | LEU A:820	ILE B: 888 | LEU B: 889 | LYS B: 868 | VAL B: 916 | VAL B: 914
		2	-92.0206	-81.2006			ASN A: 818 | ARG A: 817 | ASP A: 831 | LEU A: 694 | LYS A: 721 | MET A: 769	ASP B: 1046 | CYS B: 1045 | ILE B: 1044
		3	-98.3471	-81.5223				
		4	-101.451	-81.1558				
		5	-90.0179	-81.6199			VAL A: 702	

		6	-98.9981	-81.9695				ALA B: 881 | SER B: 884
		7	-94.6642	-81.9707				HIS B: 1026 | GLU B:885
		8	-96.2757	-82.0085				
		9	-95.9779	-78.5779				
		10	-99.4359	-71.3232				
13	*29-Hydroxyceanothenic acid*	1	-62.2838	-70.191			CYS A: 773 | LEU A: 820 | LEU A: 694 | VAL A: 702	CYS B: 1024 | LEU B: 1019 | VAL B: 899 | HIS B: 1026 | VAL B: 898 | ILE B: 892 | LEU B: 889
		2	-65.1637	-70.9446				
		3	-65.7841	-70.518				
		4	-65.6273	-71.0135			GLY A: 700 | ARG A: 817	ASP B: 1024
		5	-65.4392	-70.795				ARG B: 1027 | LYS B: 8

		6	-61.8453	-70.5191			LYS A: 721	SER B: 884
		7	-64.5875	-71.2725				
		8	-65.6295	-71.8428				
		9	-65.0515	-70.0557				
		10	-70.9519	-71.8839				
14	*Isorhamnetin3-O-[6-P-coumaroyl]- β –Dglucopyranoside*	1	-94.1843	-67.86			SER A: 696	GLY B: 841 | ARG B: 842
		2	-89.3218	-76.6866			ALA A: 719 | LEU A; 820 | LEU A: 694 | VAL A: 702	LEU B: 840 | ASN B: 923 | ASP B:1028
		3	-89.7033	-67.6864				
		4	-92.6322	-71.202				
		5	-92.2492	-71.7929			ASP A: 831 | LYS A: 721 | MET A: 769	PHE B: 1047
		6	-94.169	-77.4794			THR A: 766	ARG B: 1032 | LYS B: 868 | VAL B: 848
		7	-99.4354	-78.4724				
		8	-98.8743	-76.6659				
		9	-95.063	-77.3537				ASN B: 1033
		10	-97.1218	-76.7542				
15	*Quercetin 3-O-β-D-glucopyranoside*	1	-90.6375	-82.1864			ASN A: 818 | ARG A: 817 | ASP A: 831 | LYS A:	ASP B:1046 GLU B:885 CYS B:919 GLU B:917 ILE B:1044

		2	-94.495	-88.3768			721 | GLY A: 700 | MET A: 769 | THR A: 766	LYS B:868 PHE B:918
		3	-97.6928	-82.8513				
		4	-97.2976	-82.1932			LEU A: 694	VAL B:916 VAL B:848 ALA B:866 LEU B:1035 CYS B:1045 PHE B:1047
		5	-96.1914	-87.2556			ALA A: 719 | VAL A: 702	
		6	-91.5309	-82.5479				
		7	-94.5005	-84.7332				
		8	-93.7521	-83.5942				
		9	-98.8391	-82.1786				
		10	-99.3072	-81.383				
16	*Quercetin 3-O-α-L-rhamnopyranoside*	1	-62.5748	-73.267			CYS A: 773 | LYS A: 721	VAL B: 898 | VAL B:899 | LEU B:889 | ILE B:888
		2	-62.0981	-71.974			ARG A: 817	
		3	-62.9055	-73.3643				
		4	-62.0243	-72.7641				
		5	-62.8054	-73.4887				HIS B: 1026 | GLU B: 885
		6	-63.8583	-72.2509				
		7	-62.3402	-72.4392				
		8	-62.4401	-72.2213				
		9	-63.7464	-71.9854				

		10	-62.4672	-71.8779				
17	*Zizyberenalic acid*	1	-61.8626	-72.4532			ARG A: 817	LEU B: 889 | ILE B: 888 | VAL B: 916 | VAL B: 899 | VAL B: 898
		2	-61.9684	-73.1799			LYS A: 721 | CYS A: 773	
		3	-62.9595	-73.4741				
		4	-61.841	-72.3894				HIS B: 1026, GLU B: 885
		5	-62.2234	-72.8737				
		6	-62.3306	-72.626				
		7	-63.9997	-72.222				
		8	-64.2479	-72.4952				
		9	-62.6185	-72.4685				
		10	-62.4948	-72.1486				
18	*Ceanothenic acid*	1	-62.7768	-70.099			CYS A: 773 | LEU A: 820 | LEU	ARG B: 1027 | LYS B: 868

							A:694 | VAL A: 702	
		2	-61.5657	-69.9324			LYS A: 721	HIS B: 1026 | VAL B: 898 | VAL B: 899 | LEU B: 889
		3	-64.6444	-70.0756			LYS A: 721	ARG B: 1027
		4	-65.5028	-69.921				
		5	-62.1194	-70.1319				
		6	-63.1049	-70.1574				
		7	-65.342	-70.1583				
		8	-63.9933	-70.0934				
		9	-60.6763	-69.5346				
		10	-65.7592	-69.375				
19	*Isorhamnetin 3-O-rutinoside*	1	-103.678	-76.2502			LEU A:820 ALA A:719 LYS A:721 VAL A:702	LYS B: 868 | GLU B: 885
		2	-104.705	-80.6413				
		3	-106.34	-77.9292			MET A:769 LEU A:694 ASN A:818 ASP A:831	LEU B: 882 | ALA B: 881 | LEU B: 889 | CYS B: 1045 | VAL B: 899
		4	-103.509	-76.227			ARG A:817	
		5	-103.268	-73.5739				
		6	-101.867	-81.2263				ASP B: 1046

		7	-103.472	-75.7752				ARG B:1027 | HIS B: 1026 | ILE B:1025 | PHE B: 1047 | ILE B:1044
		8	-95.4106	-80.2518				
		9	-90.2581	-75.3317				
		10	-95.3586	-77.3643				
20	*Ceanothic acid*	1	-64.2546	-67.9354			LEU A: 820 | THR A: 830	ARG B: 1027 | LYS B: 868
		2	-64.548	-67.7097			CYS A: 773	HIS B: 1026 | ILE B: 888 | LEU B: 889 | ILE B:892 | LEU B: 1019 | ALA B: 881
		3	-62.2885	-69.1971			MET A: 769 | LEU A: 694 | LEU A: 768 | ALA A: 719 | VAL A: 702	
		4	-63.3863	-68.2668			LYS A: 721	
		5	-62.2229	-68.2457				
		6	-64.6381	-67.8106				
		7	-64.072	-68.0767				
		8	-62.5907	-68.2239				

		9	-63.2424	-68.0841				
		10	-63.7382	-67.6861				
21	*Adouetine X*	1	-75.7101	-89.4698			ARG A: 817 | LYS A: 721	ARG B:1027 | ILE B: 1025 | ASP B:1046
		2	-80.8638	-77.0234			THR A: 830	LEU B:1019 | ILE B:888
		3	-70.04	-88.275			ARG A:817	HIS B:1026
		4	-71.0035	-85.7145			ALA A: 719 | LEU A: 820 | LEU A: 694 | LEU A: 834 | VAL A: 702	
		5	-69.5667	-85.1106				
		6	-68.6836	-82.4631				
		7	-75.0857	-84.3491				
		8	-71.5003	-84.9554				
		9	-71.1606	-81.4203				
		10	-71.0804	-83.0354				
22	*Betulin*	1	-71.5164	-67.5525			ALA A:719 | LEU A: 820 | LEU A:694 | CYS A: 773	ARG B: 1027 | ILE B:1044
		2	-71.7878	-67.8553			VAL A: 702	

		3	-73.2387	-67.2655			LEU A: 768 MET A: 769 | GLN A: 767 | SER A: 696	ALA B: 881 | LEU B: 889 | LEU B: 1019 | HIS B: 1026 | ILE B: 892 | VAL B: 898 | ILE B: 888
		4	-71.5011	-68.2996				
		5	-73.1186	-67.2935				
		6	-70.7842	-68.9487				
		7	-72.2218	-67.5662				
		8	-72.2062	-67.7237				
		9	-70.8184	-68.7823				
		10	-72.0121	-67.531				
23	*Betulinic acid*	1	-67.6676	-71.1653			LYS A: 721	ARG B: 1027
		2	-68.4486	-72.5581			LEU A: 820 | THR A: 830	ILE B: 888 | LEU B: 1019 | HIS B: 1026 | CYS B: 1024 | ILE B: 892 | ALA B: 881
		3	-66.8775	-72.9659			LEU A: 775 | ARG A: 817 | CYS A:773 | VAL A:702 | ALA A: 719 | LEU A: 694 | MET A: 769	

		4	-66.0482	-71.3324			LYS A:721	
		5	-65.4721	-73.8353				
		6	-68.6616	-71.1752				
		7	-68.9017	-71.8649				
		8	-66.2626	-72.7139				
		9	-64.8378	-73.2217				
		10	-64.0679	-73.2851				
24	*Platanic acid*	1	-55.7656	-62.7682			MET A: 769	ARG B: 1027
		2	-55.9121	-60.9436				ILE B: 1044
		3	-55.9728	-61.3251			CYS A: 773 | LEU A:694 | LEU A: 775 | ARG A:817 | VAL A: 702 | LEU A: 820 | ALA A: 719	ILE B: 888 | HIS B: 1026 | VAL B: 898 | LEU B: 1019 | LEU B:889
		4	-56.8945	-59.8211				
		5	-56.2509	-62.8389				
		6	-56.6517	-63.3495				
		7	-57.628	-62.2835				
		8	-58.8327	-63.9969				
		9	-58.4874	-63.1373				
		10	-58.181	-64.7459				
25	*Lupeol*	1	-68.3782	-70.4803			LEU A: 820	ILE B: 888 | VAL A: 899 | LEU B: 889 VAL A:
		2	-69.9271	-70.2604			ALA A: 719 | LEU A: 694	
		3	-69.359	-71.1807				
		4	-70.5221	-69.2313				

							|MET A:769| LYS A: 721|VAL A: 702|CYS A: 773 |ARG A: 817 |LEU A: 775	898|ILE B: 892|LEU B: 1019 |HIS B: 1026
		5	-68.2541	-70.1003				
		6	-68.7616	-70.4307				
		7	-68.4646	-69.1893				
		8	-68.6821	-69.0015				
		9	-68.7187	-70.7679				
		10	-69.6924	-69.5555				
26	*(+)-Gallocatechin*	1	-84.0953	-86.2747			ALA A: 719| VAL A: 702| LEU A: 820	LEU B:840 ASN B:923 CYS B:919 GLU B:917
		2	-84.1628	-86.27			GLN A: 767|MET A: 769 |LEU A:694|THR A: 766 |LYS A: 721|ASP A: 831	PHE B:1047
		3	-83.5686	-86.3297				GLY B:922
		4	-83.0882	-86.2466				PHE B:1047 LEU B:1035 ALA B:866
		5	-83.7997	-86.2316				
		6	-84.4365	-86.3052				
		7	-83.2543	-85.9805				
		8	-84.2259	-86.2099				
		9	-83.4358	-85.9173				

		10	-83.3826	-85.6531				
27	*Corosolic acid*	1	-67.9092	-66.6492			VAL A: 702	ARG B: 1027
		2	-67.8021	-66.5047			GLN A: 767 | MET A: 769	ALA B: 881 | HIS B: 1026 | ILE B: 888 | LEU B: 1019 | LEU B: 892 | CYS B: 1024
		3	-67.8114	-63.1136			ARG A: 817 | ALA A: 719 | LEU A: 768 | LEU A: 694 | LEU A: 820 | CYS A: 773	
		4	-64.282	-69.0099				
		5	-65.5333	-60.4023			LYS A: 721	
		6	-66.555	-64.5637				
		7	-60.8429	-67.4118				
		8	-62.6081	-68.4156				
		9	-63.6732	-70.4398				
		10	-63.977	-73.7348				
28	*Maesopsin*	1	-85.4452	-78.5049			LEU A: 820 | ALA A: 719 | LYS A: 721 | LEU 764 | 764	PHE B: 1047
		2	-85.2406	-80.5067				GLU B: 917 | ASP B: 1046 | LYS B: 868 | ALA B: 866
		3	-85.2331	-80.8398				
		4	-85.4479	-77.6907			THR A: 766 | GLN A: 767	
		5	-85.3693	-80.5155				LEU B: 1035 | CYS B:919 | CYS B: 1045 | VAL

								B: 916 | VAL B: 848
		6	-85.4493	-80.6725				
		7	-85.4199	-78.8763				
		8	-85.2116	-79.6688				
		9	-85.3704	-78.1647				
		10	-85.2596	-77.2723				
29	*Isorhamn etin3-O- (6''-O-(Z)-p-coumaroy l)-β-D-glucopyranoside*	1	-87.8293	-89.148			GLN A: 952	ASP B:1046 ASP B:1028 ILE B:1025 HIS B:1026 | ARG B: 1027 ALA B:881
		2	-82.94	-78.808			ASP A: 960	LYS B:868
		3	-90.2937	-89.6252				LEU B:889
		4	-79.6792	-88.2339				ALA B:881
		5	-89.4271	-89.4431				
		6	-91.0269	-89.3831				
		7	-78.7192	-81.3176				
		8	-77.7314	-85.5314				
		9	-76.8687	-83.7469				
		10	-77.6259	-82.8692				
30	*Alphitexolide*	1	-65.6741	-74.7165			LYS A: 692	ARG B: 1027

		2	-62.7882	-73.8794			ALA A: 719 | MET A: 769 | LEU A: 820 | LEU A: 694 | CYS A: 773	ASP B: 1046
		3	-65.8147	-74.2504				CYS B: 1045
		4	-64.9095	-74.4416				ALA B: 881 | ILE B: 888 | VAL B: 899 | LEU B: 889
		5	-62.5045	-73.6452				
		6	-62.8695	-73.7185				
		7	-64.9855	-73.8383				
		8	-65.3226	-73.7268				
		9	-59.9774	-72.3338				
		10	-60.1943	-72.3205				
31	*Uridine*	1	-80.713	-69.8187			THR A: 830 | LEU A: 764 | THR A: 766 | ASP A: 831	GLU B: 885 | ASP B: 1046 | CYS B:919
		2	-80.2845	-69.849				
		3	-81.2921	-69.8069				
		4	-80.8568	-69.6303			LYS A:721	PHE B: 918
		5	-81.44	-70.0478			LEU A: 753 | MET A: 742	CYS B: 1045 | LEU B: 1035 | VAL 916 | VAL B: 899 | ALA B: 866
		6	-79.8883	-70.0753				
		7	-76.4837	-69.627				
		8	-76.8318	-69.8913				

		9	-76.7153	-69.8692				
		10	-76.2269	-69.5925				
32	*3-O-beta-D-Galactopyranosyl-quercetin*	1	-94.0572	-80.9045			MET A: 769 | THR A: 721 | ASP A: 831 | GLN A: 767 | THR A: 766 | LEU A: 764	GLU B: 885 | ILE B: 1044 | ILE B:1025 | ASP B: 1046
		2	-93.2175	-80.2223			ALA A: 719 | LEU A: 820 | VAL A: 702	ILE B: 888 | CYS B: 1024
		3	-94.3898	-80.5791			LYS A: 721	GLU B: 885
		4	-94.1567	-80.0277				
		5	-94.0227	-79.423				
		6	-93.9333	-79.019				
		7	-94.2703	-80.7465				
		8	-94.9645	-79.6008				
		9	-93.633	-79.2735				
		10	-92.826	-79.1919				
33	*β- Sitosterol*	1	-93.6912	-84.8849			ALA A: 719 | LYS A: 721 | LEU A:764 | LEU A: 753 | MET A: 742 | LEU A: 820	ILE B:1025 VAL B:899 ALA B:866 VAL B: 916 VAL B:848 LYS B:868 PHE B:1047 |
		2	-91.7533	-81.5029				
		3	-91.8599	-81.338				

							VAL A: 702	CYS B:1045 ILE B:888 CYS B:1024 LEU B:1019 LEU B:889
		4	-89.7542	-83.0922				
		5	-93.2728	-85.1163				
		6	-93.3453	-86.2919				
		7	-93.401	-82.3892				
		8	-92.4317	-81.1126				
		9	-93.2833	-84.869				
		10	-95.6451	-83.1141				